Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
about
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models.Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Functional characterization of a unique cytochrome P450 in Toxoplasma gondii.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
P2860
Q39137457-88C62E28-2F59-4122-870E-0BE8A30D6628Q45057327-26AEEC55-921D-4C8B-B7D0-A5D75988725EQ47411365-008B76EF-A716-4691-AED0-5BA575320B26Q47553423-4F0B663C-A501-4B77-9AE0-C863EBF72690Q47610956-A1AC2CF9-2AA1-4AF1-AD8F-19773102067AQ48146110-2F2F946F-E0EF-4459-AC42-ED536DBDB1DAQ48154329-69D03ED3-A966-42C3-8EBE-EB6352CDBFCBQ48257454-541A5B60-C36C-407A-9EB0-5DEB9B10B106Q49353484-B3CE0C27-61C1-4804-A09B-AF0788B32AFEQ50119590-AD877E77-205F-4404-BB94-2F31FD372DA0Q51007604-2BED3BFB-EE85-4E6E-AA03-21CF34D83AB1
P2860
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@en
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@nl
type
label
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@en
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@nl
prefLabel
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@en
Effect of ketoconazole, a stro ...... nts with non-Hodgkin lymphoma.
@nl
P2093
P2860
P356
P1476
Effect of ketoconazole, a stro ...... ents with non-Hodgkin lymphoma
@en
P2093
Alexey V Danilov
David Chien
Lionel D Lewis
Martin Gutierrez
Shekman L Wong
Soham Puvvada
P2860
P304
P356
10.1111/BCP.13175
P407
P577
2017-01-18T00:00:00Z